Codice QR

Safety, Pharmacokinetics, and Efficacy of 1.5% Ruxolitinib Gel (HDM3010) in Adult Patients with Prurigo Nodularis: A Phase I/II, Randomized, Double-Blind, Vehicle-Controlled Multicenter Clinical Trial

Abstract Introduction Prurigo nodularis (PN) is a chronic inflammatory dermatosis with severe, persistent pruritus and limited effective therapies. Janus kinase (JAK) inhibition has emerged as a targeted strategy for PN. Methods This phase I/II, randomized, double-blind, vehicle-controlled, multicen...

Descrizione completa

Salvato in:
Autori principali: Chao Wu, Xuping Niu, Xiaohua Wang, Juan Su, Hengguang Zhao, Mao Lin, Chunjun Yang, Xiaoming Qin, Shuping Guo, Cunhuo Jiang, Hui Tang, Haijing Yang, Liming Wu, Min Zhu, Aihua Wei, Xiaohua Tao, Yiwen Zhang, Chang Shu, Jiawei Liu, Lu Yang, Yuetong Qian, Bingjie Zhang, Shiyu Zhang, Junfang Xu, Yang Lu, Mingjia Peng, Shizheng Luo, Weijie Ma, Hongzhong Jin
Natura: Artigo
Lingua:Inglês
Pubblicazione: Adis, Springer Healthcare 2026-05-01
Serie:Dermatology and Therapy
Soggetti:
Prurigo nodularis
JAK inhibitor
Ruxolitinib gel
Safety
Pharmacokinetics
Efficacy
Accesso online:https://doi.org/10.1007/s13555-026-01787-x
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi